US2020239566A1PendingUtilityA1
Anti-tlr4 antibodies and uses thereof
Est. expiryJan 10, 2031(~4.5 yrs left)· nominal 20-yr term from priority
C07K 16/2896A61K 39/3955C07K 2317/24A61P 37/06A61K 2039/505A61P 43/00A61K 2039/515C07K 16/28A61K 2039/577C07K 2317/54C07K 2317/55C07K 2317/21A61K 2035/122A61K 45/06A61K 2039/507A61K 35/14A61K 35/39
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention relates generally to antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and to methods of using the anti-TLR4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.
Claims
exact text as granted — not AI-modified1 . A method of inhibiting rejection of or prolonging survival of transplanted biological material in a subject, the method comprising:
(i) contacting the biological material to be transplanted with an antibody or immunologically active fragment thereof that specifically binds a Toll-like receptor 4 (TLR4) polypeptide to produce a transplantable composition, and (ii) implanting the transplantable composition at a desired location in the subject.
2 - 26 . (canceled)Join the waitlist — get patent alerts
Track US2020239566A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.